TrialCompass TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT05296304

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing Bexarotene and Total Skin Electron Beam (TSEB) for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 3 US locations.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Bexarotene (DRUG): Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study. | Total Skin Electron Beam (TSEB) (RADIATION): At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).

Drugs / treatments
Bexarotene, Total Skin Electron Beam (TSEB)
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

NCT05296304

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing Bexarotene and Total Skin Electron Beam (TSEB) for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 3 US locations.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Bexarotene (DRUG): Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study. | Total Skin Electron Beam (TSEB) (RADIATION): At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).

Drugs / treatments: Bexarotene, Total Skin Electron Beam (TSEB)

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 20 patients

Primary endpoint: Incidence of radiation dermatitis grade 3+

Ages: 18 Years to —

Start date: 2022-03-16 | Est. completion: 2027-03

Locations

3 US sites · 3 total

New York

Contact

Brandon Imber, MD, MS | imberb@mskcc.org | 631-212-6346

Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05296304

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.